Nama's AI scorecard currently rates Harmony Biosciences Buy (8.1 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is HRMY's P/E ratio?

Harmony Biosciences trades at a trailing price-to-earnings ratio of 9.0.

When does HRMY report earnings?

Harmony Biosciences's next scheduled report is on Feb 23, 2027. Analysts expect EPS of $1.53.

What is the HRMY price target?

The median analyst price target from 12 analysts is $49.50, with a range of $30.00 – $70.00.

Is HRMY Shariah compliant?

Nama's AAOIFI-style screen reads Harmony Biosciences as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Harmony Biosciences (HRMY)

Healthcare · Biotechnology · NASDAQ

Harmony Biosciences (HRMY) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $1.94B, a trailing price-to-earnings ratio of 9.0 and a free-cash-flow yield of 17.9%. Over the most recent reported fiscal year, revenue grew 21.5% and free cash flow per share grew 57.3%. Nama's AI scorecard rates it Buy, 8.1 out of 10. On 12-month momentum it ranks in the rising band of its market.

AI scorecard

Buy · 8.1/10

Clearly positive, short of the top band. As of Nov 7, 2026.

Momentum

Rising · +27.1% over 12 months ex. last

Second-best fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-46.7%

How far the last close sits under the highest price of the past five years.

Market cap	$1.94B
Trailing P/E	9.0
Price / book	1.9
Price / sales	2.0
FCF yield	17.9%
Dividend yield	—
Gross margin	75.4%
Operating margin	24.0%
Net margin	18.9%
Revenue growth (YoY)	+21.5%
Revenue growth (3-yr annual)	+25.6%
EPS growth (YoY)	-10.9%
FCF/share growth (YoY)	+57.3%
Beta	1.0
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

HRMY earnings

Next report: Feb 23, 2027 (Q4 2026, EPS estimate $1.53). Beat the EPS estimate in 1 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 4, 2026	$0.81	$1.09	-25.7%	$268.92M
Q2 2026	Aug 4, 2026	$1.50	$1.15	+30.4%	$261.28M
Q1 2026	May 7, 2026	$0.79	$0.93	-15.1%	$215.39M
Q4 2025	Feb 24, 2026	$0.57	$1.07	-46.7%	$243.78M

HRMY analyst price target

Median target $49.50 from 12 analysts, ranging $30.00 – $70.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live HRMY data on Nama Insights →

HRMY FAQ

Is HRMY a buy?: Nama's AI scorecard currently rates Harmony Biosciences Buy (8.1 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is HRMY's P/E ratio?: Harmony Biosciences trades at a trailing price-to-earnings ratio of 9.0.
When does HRMY report earnings?: Harmony Biosciences's next scheduled report is on Feb 23, 2027. Analysts expect EPS of $1.53.
What is the HRMY price target?: The median analyst price target from 12 analysts is $49.50, with a range of $30.00 – $70.00.
Is HRMY Shariah compliant?: Nama's AAOIFI-style screen reads Harmony Biosciences as Not Shariah Compliant. At least one of the three ratios or the industry test failed.